论文部分内容阅读
目的观察瑞舒伐他汀对poloxamer 407(P-407)诱导的小鼠高血脂模型血脂水平的影响。方法小鼠于腹腔注射P-407前先以瑞舒伐他汀(2或10 mg/kg)连续灌胃,并于腹腔注射P-407(0.3 g/kg)后3 h再次灌胃瑞舒伐他汀。以注射P-407前及注射后第3、4、24及48 h血甘油三酯和胆固醇水平评价瑞舒伐他汀的疗效,同时观察造模后24 h高密度脂蛋白-胆固醇水平。结果瑞舒伐他汀组血清甘油三酯和胆固醇水平减低,具有显著的量效关系,且作用可持续至造模后的48 h。瑞舒伐他汀组小鼠造模后24 h血清高密度脂蛋白-胆固醇水平显著升高(P<0.05)。结论瑞舒伐他汀可有效降低P-407诱导的高血脂模型小鼠的血脂水平。
Objective To investigate the effect of rosuvastatin on plasma lipid levels induced by poloxamer 407 (P-407) in mice with hyperlipidemia. Methods Mice were orally administrated with rosuvastatin (2 or 10 mg / kg) intraperitoneally before intraperitoneal injection of P-407 and re-administered with rosuvastatin 3 h after intraperitoneal injection of P-407 (0.3 g / kg) Statin. The effects of rosuvastatin on triglyceride and cholesterol levels were evaluated before injection of P-407 and at the 3rd, 4th, 24th and 48th hour after injection. The levels of high-density lipoprotein-cholesterol at 24 hours after modeling were also observed. Results Serum triglyceride and cholesterol levels were decreased in rosuvastatin group with a significant dose-effect relationship, and the effect lasted until 48 h after modeling. Serum high-density lipoprotein-cholesterol levels were significantly increased in rosuvastatin-treated mice 24 h after modeling (P <0.05). Conclusion Rosuvastatin can effectively reduce the lipid level of P-407-induced hyperlipidemia model mice.